Trial · NCT07903259
Effect of Paracetamol Administration Timing on Oxidative Stress in Children Undergoing Sevoflurane Anesthesia
NCT07903259, Phase 4, Completed, University of Belgrade
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Paracetamol Administration Timing on Oxidative Stress in Children Undergoing Sevoflurane Anesthesia. Trials, record NCT07903259. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903259
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Paracetamol Administration Timing on Oxidative Stress in Children Undergoing Sevoflurane Anesthesia
- NCT number
- NCT07903259
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 49 participants, actual
- Lead sponsor
- University of Belgrade
- Conditions
- Oxidative Stress, Sevoflurane Anaesthesia
- Interventions
- paracetamol (acetaminophen) solution commercial
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Erythrocyte Superoxide Dismutase (SOD) Activity | Four perioperative sampling points, from baseline to the final blood sample before surgical incision | Erythrocyte superoxide dismutase (SOD) activity was measured spectrophotometrically and expressed in U/g Hb. Changes across four predefined blood sampling points were evaluated and compared between the two paracetamol administration groups. |
| Primary | Change in Erythrocyte Catalase (CAT) Activity | Four perioperative sampling points, from baseline to the final blood sample before surgical incision. | Erythrocyte catalase (CAT) activity was measured spectrophotometrically as an indicator of antioxidant defense. Changes across four predefined blood sampling points were evaluated and compared between the two paracetamol administration groups. |
| Primary | Change in Erythrocyte Glutathione Peroxidase (GPx) Activity | Four perioperative sampling points, from baseline to the final blood sample before surgical incision. | Erythrocyte glutathione peroxidase (GPx) activity was measured spectrophotometrically as an indicator of enzymatic antioxidant defense. Changes across four predefined blood sampling points were evaluated and compared between the two paracetamol administration groups. |
| Primary | Change in Erythrocyte Glutathione Reductase (GR) Activity | Four perioperative sampling points, from baseline to the final blood sample before surgical incision. | Erythrocyte glutathione reductase (GR) activity was measured spectrophotometrically as an indicator of enzymatic antioxidant defense. Changes across four predefined blood sampling points were evaluated and compared between the two paracetamol administration groups. |
| Primary | Change in Plasma Malondialdehyde (MDA) Concentration | Four perioperative sampling points, from baseline to the final blood sample before surgical incision. | Plasma malondialdehyde (MDA) concentration was measured as a marker of lipid peroxidation and oxidative stress. Changes across four predefined blood sampling points were evaluated and compared between the two paracetamol administration groups. |
| Primary | Change in Plasma Total Sulfhydryl (SH) Group Levels | Four perioperative sampling points, from baseline to the final blood sample before surgical incision. | Plasma total sulfhydryl (SH) group levels were measured using a spectrophotometric method based on 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) as an indicator of plasma antioxidant status. Changes across four predefined blood sampling points were evaluated and compared between the two paracetamol administration groups. |
| Primary | Change in Plasma Total Glutathione Concentration | Four perioperative sampling points, from baseline to the final blood sample before surgical incision. | Plasma total glutathione concentration was measured as an indicator of antioxidant defense and redox homeostasis. Changes across four predefined blood sampling points were evaluated and compared between the two paracetamol administration groups. |
| Primary | Change in Plasma Superoxide Dismutase (SOD) Activity | Four perioperative sampling points, from baseline to the final blood sample before surgical incision. | Plasma superoxide dismutase (SOD) activity was measured as an indicator of extracellular antioxidant defense. Changes across four predefined blood sampling points were evaluated and compared between the two paracetamol administration groups. |
| Primary | Change in Plasma Nitric Oxide Metabolite (NOx) Concentration | Four perioperative sampling points, from baseline to the final blood sample before surgical incision. | Plasma nitric oxide metabolites (NOx), comprising nitrite and nitrate, were measured using the Griess reaction following nitrate reduction. Changes across four predefined blood sampling points were evaluated and compared between the two paracetamol administration groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903259
GET https://conductscience.org/api/trials/v1/NCT07903259/registered